5/16
04:05 pm
spro
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Low
Report
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
5/16
08:15 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
5/15
04:20 pm
spro
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update [Yahoo! Finance]
Low
Report
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update [Yahoo! Finance]
5/15
04:05 pm
spro
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Low
Report
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
5/8
08:00 am
spro
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
Low
Report
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
5/1
04:21 pm
spro
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
5/1
04:07 pm
spro
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/23
11:51 am
spro
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value [Seeking Alpha]
Low
Report
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value [Seeking Alpha]
4/4
10:09 am
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
3/18
02:52 pm
spro
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
3/17
09:27 am
spro
Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]
Low
Report
Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]
3/15
01:02 pm
spro
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/15
07:16 am
spro
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market? [Yahoo! Finance]
Medium
Report
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market? [Yahoo! Finance]
3/14
09:31 am
spro
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
Medium
Report
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
3/13
04:21 pm
spro
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update [Yahoo! Finance]
Low
Report
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update [Yahoo! Finance]
3/13
04:01 pm
spro
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Medium
Report
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
3/6
08:05 am
spro
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
Medium
Report
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024